Life Biosciences is a privately held company tracked for investment-relevant business and technology developments.
This slot renders the company's funding history: dates, rounds, amounts, valuations and lead investors once populated in data/funding-rounds.json.
Peter Diamandis' portfolio company Life Biosciences has dosed 18 patients with ER100 (three Yamanaka factors via viral vector) in a human trial for glaucoma and optic nerve damage, with primate data showing reversal of macular degeneration and non-ion disease; results expected in 6-12 months.